Skip to content
    Back to Database
    Novel and Emerging IngredientsSynthetic

    UthPeak NMNH

    Also known as: NMNH, Dihydro-NMN, UthPeak

    Dihydro form of NMN; preclinical studies suggest faster and higher NAD+ elevation than oxidised NMN; clinical replication is limited.

    Last reviewed: 2026-06-23 · 1 indexed study

    Evidence Score
    42/100
    Reduced-NAD+ precursorLongevityCellular energy
    Data Completeness3/4 · 75%
    Evidence ScoreDosageSafetyLinked Studies

    Set your location for accurate regulatory status

    Saved on this device — no sign-in needed.

    Sign in to add to stack

    Overview

    UthPeak (NMNH) is a reduced form of NMN claimed to raise NAD+ more efficiently than oxidised NMN; clinical human data is preliminary.

    Mechanism & Function

    Mechanism of Action

    Acts as a direct NAD+ precursor with potentially higher efficiency than oxidised NMN in preclinical models.

    Physiological Role

    Marketed as a next-generation NMN; ergogenic and longevity benefits should be considered probable but unproven in humans.

    Primary Pathways

    NAD+ biosynthesisSirtuin activationMitochondrial biogenesis

    Performance / Health Relevance

    Preclinical animal data positive; human trials very limited.

    Evidence Review

    Overall42/100
    Human ClinicalN/A

    No human clinical studies indexed for this ingredient yet.

    Meta-AnalysisN/A

    No meta-analyses or systematic reviews indexed for this ingredient yet.

    Mechanistic78/100
    Real-World42/100
    Safety75/100

    Dimensions marked N/A have no indexed evidence of that class. They are shown as unavailable rather than scored.

    Practical Use & Dosage

    Minimum Effective Dose
    50 mg/day
    Optimal Range
    100–250 mg/day
    Upper / Caution Level
    ~500 mg/day
    Timing
    Morning
    Best Format
    Capsule
    Bioavailability
    Manufacturer data suggest superior NAD+ kinetics vs NMN.
    Absorption Considerations
    Mechanism similar to NMN; human PK data limited.

    Safety & Interactions

    Side Effects

    • •Insufficient long-term data

    Contraindications

    • Active cancer (theoretical)

    Drug Interactions

    • •None established

    Who Should Avoid

    • •Pregnancy (no data)

    Monitoring

    None routine.

    Frequently Asked Questions

    Auto-generated from indexed evidence — dosage, safety, interactions, and more.

    When is UthPeak NMNH typically used or indicated?

    UthPeak NMNH is most commonly used for: Reduced-NAD+ precursor, Longevity, Cellular energy. Marketed as a next-generation NMN; ergogenic and longevity benefits should be considered probable but unproven in humans.

    How does UthPeak NMNH work?

    Acts as a direct NAD+ precursor with potentially higher efficiency than oxidised NMN in preclinical models.

    What is the recommended dose of UthPeak NMNH?

    The optimal range is 100–250 mg/day. with a minimum effective dose of 50 mg/day. Best taken: Morning. Upper / caution level: ~500 mg/day.

    What are the side effects of UthPeak NMNH?

    Reported side effects include: Insufficient long-term data. Monitoring: None routine.

    Does UthPeak NMNH interact with medications?

    Known or theoretical interactions: None established. Always check with a clinician before combining with prescription medication.

    Who should avoid UthPeak NMNH?

    UthPeak NMNH is generally not recommended for: Pregnancy (no data); and Active cancer (theoretical).

    How strong is the evidence for UthPeak NMNH?

    Evidence level: Limited (overall score 42/100), based on 1 indexed study on SuppIndex.

    Research & References (1)

    NMNH vs NMN in NAD+ elevation: preclinical comparison

    Animal2022Low
    PubMed

    NMNH produced faster and higher NAD+ elevation than NMN in murine tissue.

    Trademark Ingredients

    UthPeak™

    Manufacturer:

    Related Ingredients

    Other top-rated ingredients in Novel and Emerging Ingredients.

    Trans-Resveratrol

    62/100

    Trans-isomer of resveratrol; activates SIRT1, modulates AMPK, and provides antioxidant defence; rapidly metabolised to sulfate/glucuronide conjugates.

    NMN

    54/100

    Nicotinamide riboside monophosphate; converted to NAD+ via NMNAT enzymes; supports mitochondrial energy, DNA repair, and sirtuin-mediated longevity pathways.

    Urolithin A

    52/100

    A gut-derived dibenzopyranone metabolite of ellagitannins that activates mitophagy (selective autophagy of damaged mitochondria) via PINK1/Parkin and AMPK/ULK1 signaling pathways.

    Research Overview

    Limited Evidence
    1Total Studies
    0Human Trials
    0Meta-Analyses
    2022Latest Study
    1Animal / In Vitro
    0Athlete Studies
    Primary data sourceAnimal
    Pooled evidence (meta-analysis / systematic review)No

    Cite this ingredient

    One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.

    Stable URL

    https://thesuppindex.com/ingredients/uthpeak-nmnh

    SuppIndex. (2026). UthPeak NMNH: Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/uthpeak-nmnh

    Based on 1 indexed studies · Evidence level: Limited.

    Goal Ratings

    General Health
    Recovery

    Stack Compatibility

    Pair with TMG and resveratrol for sirtuin/methylation support.

    TMGTrans-ResveratrolPterostilbene